HIF1A and melanoma: For this reason, a number of HIF-1α inhibitors have been used in combination with standard chemotherapy to treat melanomas (53), breast cancer (54), and GBMs (55) in clinical trials in which it has been found that HIF-1α inhibition increases tumor response to treatment and leads to a reduction of the tumor progression rate, thus making it an interesting new therapeutic option (24, 56–58).